Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to evaluate the safety/tolerability, pharmacokinetic, and pharmaco-dynamic effects of KA2507 and establish the maximum tolerated dose (MTD). Patients with PD-L1 expressing solid tumors which have relapsed or are refractory to prior treatment will be eligible to participate in this study.

Following completion of the multiple ascending dose study, the protocol may be amended to include expansion cohorts in patients with melanoma and/or other solid tumors.


Clinical Trial Description

The aim of the study is to evaluate the safety/tolerability, pharmacokinetic, and pharmaco-dynamic effects of KA2507 and establish the maximum tolerated dose (MTD). Patients with PD-L1 expressing solid tumors which have relapsed or are refractory to prior treatment will be eligible to participate in this study.

Following completion of the multiple ascending dose study, the protocol may be amended to include expansion cohorts in patients with melanoma and/or other solid tumors.

This is a multiple ascending dosing (MAD) study of up to 6 treatment regimens cohorts based on using a 3+3 design (up to 36 patients overall). The principal objective is to establish the maximum tolerated dose, safety, tolerability and pharmacokinetic (PK) profile in blood and urine of this HDAC6 inhibitor in patients with solid tumors and to explore effects on pharmacodynamic markers of target engagement and response to treatment.

Daily/twice daily doses will be given as open label monotherapy. A review of safety and PK data will be conducted once the last patient in each cohort reaches day 28 of treatment. The review will confirm the dose to be used for the subsequent cohort. Dose escalation will be continued until the MTD is reached. Upon completion of the dose escalation phase of the study, dose expansion phases will be planned.

Patients responding to treatment may elect to remain on therapy until disease progression, death or the investigator decides to stop treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03008018
Study type Interventional
Source Karus Therapeutics Limited
Contact
Status Completed
Phase Phase 1
Start date August 7, 2017
Completion date June 10, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04551885 - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT04020185 - Safety and Efficacy Study of IMSA101 in Refractory Malignancies Phase 1/Phase 2
Recruiting NCT04526106 - First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors Phase 1
Recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Not yet recruiting NCT04899505 - Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
Recruiting NCT04121442 - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT04221204 - A Monotherapy in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT03992326 - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors Phase 1
Recruiting NCT04092673 - Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT04130516 - Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and in Combination With Pembrolizumab Phase 1/Phase 2
Active, not recruiting NCT04041310 - Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Phase 1
Not yet recruiting NCT04597541 - A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04585035 - Study to Evaluate D-1553 in Subjects With Solid Tumors Phase 1/Phase 2
Recruiting NCT04165330 - Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors Phase 1/Phase 2
Completed NCT04515043 - EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754) Phase 1
Recruiting NCT03600090 - Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer Phase 1
Not yet recruiting NCT03977766 - Feasibility of a Process of Digital Validation of Chemotherapies in a Day Treatment Unit N/A
Recruiting NCT03209401 - Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies Phase 1
Completed NCT03302325 - Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC